Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion d...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Med
Asıl Yazarlar: Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, Latagliata, Roberto
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2015
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123712/
https://ncbi.nlm.nih.gov/pubmed/26376955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.523
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller